

Sid E O'bryant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7459698/publications.pdf>

Version: 2024-02-01

179
papers

10,879
citations

61687

45
h-index

40945

97
g-index

188
all docs

188
docs citations

188
times ranked

15681
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. <i>Alzheimer's and Dementia</i> , 2023, 19, 36-43.	0.4	30
2	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research. <i>Alzheimer's and Dementia</i> , 2022, 18, 77-87.	0.4	21
3	Characterizing plasma NFL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. <i>Alzheimer's and Dementia</i> , 2022, 18, 240-250.	0.4	39
4	Analysis of a precision medicine approach to treating Parkinson's disease: Analysis of the DATATOP study. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 15-21.	1.1	3
5	Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12267.	1.2	18
6	Subjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100126.	0.4	1
7	Vascular risk profile and white matter hyperintensity volume among Mexican Americans and non-Hispanic Whites: The HABLE study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12263.	1.2	2
8	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12298.	1.2	6
9	Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2022, 18, 1744-1753.	0.4	4
10	Metabolic Factors Are Related to Brain Amyloid Among Mexican Americans: A HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1745-1750.	1.2	5
11	Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1677-1686.	0.4	16
12	Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1243-1254.	1.2	6
13	Cardiovascular Risk Factors, Cognitive Dysfunction, and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2021, 10, 154-162.	0.6	6
14	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 671-681.	1.2	23
15	Recursive Support Vector Machine Biomarker Selection for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1691-1700.	1.2	26
16	Relationship of Neurofilament Light (NFL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. <i>Current Alzheimer Research</i> , 2021, 17, 1214-1220.	0.7	9
17	A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 557-568.	1.2	13
18	Polypharmacy and Cognition Function Among Rural Adults. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 607-619.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Acute Regression in Down Syndrome. <i>Brain Sciences</i> , 2021, 11, 1109.	1.1	3
20	Using Fractional Anisotropy Imaging to Detect Mild Cognitive Impairment and Alzheimer's Disease among Mexican Americans and Non-Hispanic Whites: A HABLE Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 266-273.	0.7	7
21	The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12202.	1.2	36
22	MRI biomarkers of small vessel disease and cognition: A cross-sectional study of a cognitively normal Mexican American cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12236.	1.2	2
23	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. <i>Frontiers in Psychology</i> , 2021, 12, 774049.	1.1	4
24	Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing. <i>Frontiers in Artificial Intelligence</i> , 2021, 4, 798962.	2.0	4
25	Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 608862.	1.4	2
26	Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12023.	1.2	9
27	Human plasma biomarker responses to inhalational general anaesthesia without surgery. <i>British Journal of Anaesthesia</i> , 2020, 125, 282-290.	1.5	27
28	Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1049-1059.	1.2	6
29	Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12033.	1.2	4
30	Combining Select Blood-Based Biomarkers with Neuropsychological Assessment to Detect Mild Cognitive Impairment among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 739-750.	1.2	3
31	ApoE Genotype-Dependent Response to Antioxidant and Exercise Interventions on Brain Function. <i>Antioxidants</i> , 2020, 9, 553.	2.2	4
32	Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium's Down Syndrome (ABC-DS) study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12039.	1.2	13
33	Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. <i>Developmental Neurobiology</i> , 2019, 79, 699-710.	1.5	16
34	Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer's Disease-Precursor Phenotypes, and Metabolic Morbidities. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 733-749.	1.2	21
35	Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity. <i>Frontiers in Neuroscience</i> , 2019, 13, 1005.	1.4	76
36	Blood Biomarkers for Use in Alzheimer Disease—Moving From "What" to "How". <i>JAMA Neurology</i> , 2019, 76, 1009.	4.5	15

#	ARTICLE	IF	CITATIONS
37	Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 374-382.	1.2	20
38	Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama. <i>Current Aging Science</i> , 2019, 11, 236-241.	0.4	11
39	A proteomic signature for dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 270-276.	1.2	18
40	Vascular Depression and Cognition in Mexican Americans. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 68-78.	0.7	8
41	Circulating mitochondrial DNA: New indices of type 2 diabetes-related cognitive impairment in Mexican Americans. <i>PLoS ONE</i> , 2019, 14, e0213527.	1.1	45
42	The relationship of CRP and cognition in cognitively normal older Mexican Americans. <i>Medicine (United States)</i> , 2019, 98, e15605.	0.4	23
43	Blood-based protein predictors of dementia severity as measured by Î: Replication across biofluids and cohorts. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 763-774.	1.2	2
44	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
45	Levels of Î±-2 Macroglobulin in cognitively normal Mexican-Americans with Subjective Cognitive Decline: A HABLE Study. <i>Current Neurobiology</i> , 2019, 10, 22-25.	1.0	2
46	Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1485-1492.	1.2	8
47	Odorant Item Specific Olfactory Identification Deficit May Differentiate Alzheimer Disease From Aging. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 835-846.	0.6	26
48	Texas Mexican American adult normative studies: Normative data for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). <i>Developmental Neuropsychology</i> , 2018, 43, 27-35.	1.0	12
49	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	1.2	96
50	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
51	Texas Mexican American adult normative studies: Normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. <i>Developmental Neuropsychology</i> , 2018, 43, 1-26.	1.0	52
52	F501: PROTEOMIC BIOMARKERS FOR DETECTING AND PREDICTING AD RISK AMONG ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1624.	0.4	3
53	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
54	Factor structure and measurement invariance of a neuropsychological test battery designed for assessment of cognitive functioning in older Mexican Americans. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 536-544.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	4.9	434
56	A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 97-104.	1.2	36
57	The Link between Potassium and Mild Cognitive Impairment in Mexican-Americans. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 151-157.	0.6	16
58	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2018, 1750, 139-155.	0.4	12
59	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , 2017, 13, 727-738.	0.4	166
60	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 60-72.	1.2	29
61	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.4	14
62	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β -amyloid load in an AD cohort. <i>Scientific Reports</i> , 2017, 7, 14057.	1.6	22
63	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
64	Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. <i>International Psychogeriatrics</i> , 2017, 29, 1693-1699.	0.6	15
65	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017, 13, 45-58.	0.4	227
66	[FTS5â€“02â€“07]: HEALTH DISPARITIES IN ALZHEIMER'S DISEASE AMONG MEXICAN AMERICANS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1450.	0.4	0
67	Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study. <i>Journal of Translational Medicine</i> , 2017, 15, 258.	1.8	22
68	A Depressive Endophenotype for Predicting Cognitive Decline among Mexican American Adults and Elders. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 201-206.	1.2	8
69	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	1.2	44
70	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 41, 200.e13-200.e20.	1.5	174
71	Introduction to special issue on Advances in blood-based biomarkers of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 110-112.	1.2	11
72	IL-7 and Depression: The importance of gender and blood fraction. <i>Behavioural Brain Research</i> , 2016, 315, 147-149.	1.2	7

#	ARTICLE	IF	CITATIONS
73	A blood screening test for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 83-90.	1.2	54
74	Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 897-901.	1.2	7
75	Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. <i>Neurodegenerative Disease Management</i> , 2016, 6, 203-213.	1.2	23
76	An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, 88-96.	0.3	10
77	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
78	Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican-Americans. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 129-136.	1.2	42
79	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
80	Biomarkers in Sporadic and Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 291-317.	1.2	75
81	Molecular Markers of Amnesic Mild Cognitive Impairment among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 221-228.	1.2	15
82	A depressive endophenotype of poorer cognition among cognitively healthy community-dwelling adults: results from the Western Australia memory study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 881-886.	1.3	9
83	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015, 11, 549-560.	0.4	205
84	Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2023-2028.	1.3	23
85	S5-01-02: Blood biomarker assays. , 2015, 11, P302-P302.		0
86	An item response theory analysis of the Executive Interview and development of the EXIT8: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 229-242.	0.8	8
87	Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 24.	3.0	8
88	Molecular markers of neuropsychological functioning and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 61-66.	1.2	7
89	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.4	213
90	Can Genetic Analysis of Putative Blood Alzheimer's Disease Biomarkers Lead to Identification of Susceptibility Loci?. <i>PLoS ONE</i> , 2015, 10, e0142360.	1.1	13

#	ARTICLE	IF	CITATIONS
91	Oxidative Stress, Testosterone, and Cognition among Caucasian and Mexican-American Men with and without Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 563-573.	1.2	40
92	The Link between Sleep Disturbance and Depression among Mexican Americans: A Project FRONTIER Study. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 427-431.	1.4	9
93	Executive Functioning and the Metabolic Syndrome: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 47-53.	0.3	28
94	Arsenic exposure, AS3MT polymorphism, and neuropsychological functioning among rural dwelling adults and elders: a cross-sectional study. <i>Environmental Health</i> , 2014, 13, 15.	1.7	23
95	Molecular Neuropsychology: Creation of Test-Specific Blood Biomarker Algorithms. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 37, 45-57.	0.7	13
96	Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 300-309.	0.7	11
97	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 115-131.	0.4	250
98	Comparison of the accuracy of kriging and IDW interpolations in estimating groundwater arsenic concentrations in Texas. <i>Environmental Research</i> , 2014, 130, 59-69.	3.7	198
99	The Hachinski Ischemic Scale and cognition: the influence of ethnicity. <i>Age and Ageing</i> , 2014, 43, 364-369.	0.7	17
100	Regional specific groundwater arsenic levels and neuropsychological functioning: a cross-sectional study. <i>International Journal of Environmental Health Research</i> , 2014, 24, 546-557.	1.3	18
101	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 109-114.	0.4	138
102	Combining Select Neuropsychological Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A Molecular Neuropsychology Approach. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 635-640.	1.2	13
103	Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1325-1335.	1.2	73
104	The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 887-896.	1.2	15
105	O4-11-03: A PROINFLAMMATORY ENDOPHENOTYPE PREDICTS TREATMENT RESPONSE IN A MULTICENTER TRIAL OF NSAIDS IN AD. , 2014, 10, P273-P274.		3
106	P3-086: APOE4 GENOTYPE IMPACTS ACCURACY OF BLOOD ALGORITHM FOR DISTINGUISHING MCI FROM AD. , 2014, 10, P659-P660.		0
107	Cognitive differences among depressed and non-depressed MCI participants: a project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 377-382.	1.3	35
108	The impact of GPX1 on the association of groundwater selenium and depression: a project FRONTIER study. <i>BMC Psychiatry</i> , 2013, 13, 7.	1.1	32

#	ARTICLE	IF	CITATIONS
109	Androgen receptor gene and sex-specific Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2077.e19-2077.e20.	1.5	13
110	Risk factors for mild cognitive impairment among Mexican Americans. <i>Alzheimer's and Dementia</i> , 2013, 9, 622.	0.4	79
111	A brief Spanish-English equivalent version of the Boston Naming Test: A Project FRONTIER Study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 835-845.	0.8	12
112	Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 363-371.	1.2	73
113	Executive Functioning as a Mediator of the Relationship Between Premorbid Verbal Intelligence and Health Risk Behaviors in a Rural-Dwelling Cohort: A Project FRONTIER Study. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 169-179.	0.3	5
114	Normative Performance on the Brief Smell Identification Test (BSIT) in a Multi-Ethnic Bilingual Cohort: A Project FRONTIER Study. <i>Clinical Neuropsychologist</i> , 2013, 27, 946-961.	1.5	52
115	Biomarkers of Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 841-849.	1.2	69
116	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 701-706.	1.2	45
117	A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e68848.	1.1	22
118	Diagnostic Accuracy of the MMSE in Detecting Probable and Possible Alzheimer's Disease in Ethnically Diverse Highly Educated Individuals: An Analysis of the NACC Database. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 890-896.	1.7	80
119	Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 353-360.	0.6	6
120	Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 429-437.	1.2	13
121	Validation of a Latent Variable Representing the Dementing Process. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 639-649.	1.2	45
122	Using blood markers for Alzheimer disease in clinical practice?. <i>Neurology</i> , 2012, 79, 846-847.	1.5	7
123	Implication of common and disease specific variants in CLU, CR1, and PIC1M. <i>Neurobiology of Aging</i> , 2012, 33, 1846.e7-1846.e18.	1.5	36
124	Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. <i>Environmental Research</i> , 2012, 113, 52-57.	3.7	78
125	Comparison of protein concentrations in serum versus plasma from Alzheimer's patients. <i>Advances in Alzheimer's Disease</i> , 2012, 01, 51-58.	0.3	6
126	Psychological symptoms and blood pressure among rural-dwellers. <i>Journal of Health Psychology</i> , 2012, 17, 1203-1211.	1.3	2

#	ARTICLE	IF	CITATIONS
127	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 373-379.	1.2	90
128	The Relation between Inflammation and Neuropsychological Test Performance. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-6.	1.1	8
129	Normative performance on the executive clock drawing task in a multi-ethnic bilingual cohort: a project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 959-966.	1.3	16
130	Diagnostic Validity of Age and Education Corrections for the Mini-Mental State Examination in Older African Americans. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 328-331.	1.3	41
131	A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI. <i>PLoS ONE</i> , 2011, 6, e28092.	1.1	126
132	Long-Term Low-Level Arsenic Exposure Is Associated with Poorer Neuropsychological Functioning: A Project FRONTIER Study. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 861-874.	1.2	157
133	Executive functioning mediates the link between other neuropsychological domains and daily functioning: a Project FRONTIER study. <i>International Psychogeriatrics</i> , 2011, 23, 107-113.	0.6	27
134	The differential impact of depressive symptom clusters on cognition in a rural multi-ethnic cohort: a Project FRONTIER study. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 199-205.	1.3	35
135	An examination of the Boston Naming Test: calculation of an estimated 60-item score from 30- and 15-item scores in a cognitively impaired population. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 351-355.	1.3	22
136	The Influence of Thyroid Function on Cognition in a Sample of Ethnically Diverse, Rural-Dwelling Women: A Project FRONTIER Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 219-222.	0.9	8
137	Serum Brain-Derived Neurotrophic Factor Levels Are Specifically Associated with Memory Performance among Alzheimer's Disease Cases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 31-36.	0.7	60
138	A Blood-Based Algorithm for the Detection of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 55-62.	0.7	84
139	The RBANS Effort Index: Base Rates in Geriatric Samples. <i>Applied Neuropsychology</i> , 2011, 18, 11-17.	1.5	35
140	Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer's and Cognitively Normal Elderly. <i>Depression Research and Treatment</i> , 2011, 2011, 1-6.	0.7	18
141	Depression and Brain-derived Neurotrophic Factor Levels in Alzheimer's Disease. <i>Neuroscience and Medicine</i> , 2011, 02, 43-47.	0.2	5
142	Low-level groundwater arsenic exposure impacts cognition: a project FRONTIER study. <i>Journal of Environmental Health</i> , 2011, 74, 16-22.	0.5	27
143	Identifying functional impairment with scores from the repeatable battery for the assessment of neuropsychological status (RBANS). <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 525-530.	1.3	41
144	The Arsenic Exposure Hypothesis for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 311-316.	0.6	99

#	ARTICLE	IF	CITATIONS
145	The Four-Point Scoring System for the Clock Drawing Test Does Not Differentiate between Alzheimer's Disease and Vascular Dementia. <i>Psychological Reports</i> , 2010, 106, 941-948.	0.9	10
146	Diagnostic Accuracy of the RBANS in Mild Cognitive Impairment: Limitations on Assessing Milder Impairments. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 429-441.	0.3	85
147	Diagnostic Accuracy of Percent Retention Scores on RBANS Verbal Memory Subtests for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 318-326.	0.3	19
148	The Utility of the Spatial Span in a Clinical Geriatric Population. <i>Aging, Neuropsychology, and Cognition</i> , 2010, 18, 56-63.	0.7	15
149	Validation of the New Interpretive Guidelines for the Clinical Dementia Rating Scale Sum of Boxes Score in the National Alzheimer's Coordinating Center Database. <i>Archives of Neurology</i> , 2010, 67, 746-9.	4.9	186
150	Decreased C-Reactive Protein Levels in Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 49-53.	1.2	92
151	A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease. <i>Archives of Neurology</i> , 2010, 67, 1077.	4.9	210
152	On Becoming a Peer Reviewer for a Neuropsychology Journal. <i>Archives of Clinical Neuropsychology</i> , 2009, 24, 201-207.	0.3	4
153	Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 337-341.	1.2	89
154	Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: Sensitivity, specificity, and positive and negative predictive powers. <i>Archives of Clinical Neuropsychology</i> , 2008, 23, 603-612.	0.3	192
155	Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals. <i>Archives of Neurology</i> , 2008, 65, 963-7.	4.9	486
156	Clinical Utility of Trial 1 of the Test of Memory Malingering (TOMM). <i>Applied Neuropsychology</i> , 2008, 15, 113-116.	1.5	47
157	Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores. <i>Archives of Neurology</i> , 2008, 65, 1091.	4.9	607
158	The Influence of Ethnicity on Symbol Digit Modalities Test Performance: An Analysis of a Multi-Ethnic College and Hepatitis C Patient Sample. <i>Applied Neuropsychology</i> , 2007, 14, 183-188.	1.5	11
159	Test of Memory Malingering (Tomm) Trial 1 as a Screening Measure for Insufficient Effort. <i>Clinical Neuropsychologist</i> , 2007, 21, 511-521.	1.5	72
160	Examining the Test of Memory Malingering Trial 1 and Word Memory Test Immediate Recognition as Screening Tools for Insufficient Effort. <i>Assessment</i> , 2007, 14, 215-222.	1.9	68
161	Discrepancies between self-reported years of education and estimated reading level among elderly community-dwelling African-Americans: Analysis of the MOAANS data. <i>Archives of Clinical Neuropsychology</i> , 2007, 22, 327-332.	0.3	24
162	Estimating the Predictive Value of the Test of Memory Malingering: An Illustrative Example for Clinicians. <i>Clinical Neuropsychologist</i> , 2006, 20, 533-540.	1.5	60

#	ARTICLE	IF	CITATIONS
163	The Neuropsychology of Recurrent Headache. <i>Headache</i> , 2006, 46, 1364-1376.	1.8	36
164	Preliminary Findings on the Cross Cultural Test of Face Recognition. <i>Applied Neuropsychology</i> , 2006, 13, 223-229.	1.5	3
165	Neuropsychology of migraine: present status and future directions. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 363-370.	1.4	28
166	Hit Rates of Adequate Performance Based on the Test of Memory Malingering (TOMM) Trial 1. <i>Applied Neuropsychology</i> , 2005, 12, 1-4.	1.5	36
167	The Relation Between Ethnicity and Cognistat Performance in Males Seeking Substance Use Disorder Treatment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 873-885.	0.8	3
168	Discrepancies Between Self-Reported Years of Education and Estimated Reading Level: Potential Implications for Neuropsychologists. <i>Applied Neuropsychology</i> , 2005, 12, 5-11.	1.5	20
169	The California Verbal Learning Test-Children's Version: Relation to Factor Indices of the Wechsler Intelligence Scale for Children-Third Edition. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 815-822.	0.8	5
170	The relation of self-report of mood and anxiety to CVLT-C, CVLT, and CVLT-2 in a psychiatric sample. <i>Archives of Clinical Neuropsychology</i> , 2005, 20, 547-553.	0.3	16
171	Reporting of Demographic Variables in Neuropsychological Research: Trends in the Current Literature. <i>Clinical Neuropsychologist</i> , 2004, 18, 229-233.	1.5	51
172	Attenuating Demographic Influences on Verbal Fluency and Animal Naming in a Psychiatric Sample. <i>Applied Neuropsychology</i> , 2004, 11, 208-212.	1.5	5
173	Performance profiles and cut-off scores on the Memory Assessment Scales*1. <i>Archives of Clinical Neuropsychology</i> , 2004, 19, 489-496.	0.3	14
174	A review of symptoms commonly associated with menopause: implications for clinical neuropsychologists and other health care providers. <i>Neuropsychology Review</i> , 2003, 13, 145-152.	2.5	30
175	Correlations Among the TOMM, Rey-15, and MMPI-2 Validity Scales in a Sample of TBI Litigants. <i>Journal of Forensic Neuropsychology</i> , 2003, 3, 45-53.	0.7	18
176	Utility of the Trail Making Test in the Assessment of Malingering in a Sample of Mild Traumatic Brain Injury Litigants. <i>Clinical Neuropsychologist</i> , 2003, 17, 69-74.	1.5	32
177	Specificity of Malingering Detection Strategies in Older Adults Using the CVLT and WCST. <i>Clinical Neuropsychologist</i> , 2003, 17, 255-262.	1.5	36
178	The Recognition Memory Test Examination of ethnic differences and norm validity. <i>Archives of Clinical Neuropsychology</i> , 2003, 18, 135-143.	0.3	7
179	APOE ϵ 4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4